JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations

Core Insights - Jazz Pharmaceuticals (JAZZ) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.64, exceeding the Zacks Consensus Estimate of $6.62, with a year-over-year earnings increase of 2% [1] - Total revenues for the quarter rose 10% year over year to $1.2 billion, surpassing the Zacks Consensus Estimate of $1.18 billion [1] - The stock price of Jazz increased by 5% in after-market trading following the earnings report [1] Revenue Breakdown - Net product sales increased by 10.5% year over year to $1.13 billion, beating both the Zacks Consensus Estimate and the internal model estimate of $1.11 billion [3] - Royalty revenues from high-sodium oxybate authorized generic (AG) reached approximately $56 million, up 1% year over year, exceeding the Zacks Consensus Estimate of $53 million [3] - Other royalties and contract revenues amounted to about $10 million, reflecting a 28% increase from the previous year [4] Neuroscience Segment Performance - Sales of neuroscience products rose over 8% year over year to $792 million [5] - Combined net product sales for the oxybate business (Xyrem + Xywav) increased by 12% to $503 million, surpassing the Zacks Consensus Estimate of $481 million [5] - Xywav sales grew by 16% to over $465 million, attributed to strong uptake in narcolepsy and idiopathic hypersomnia indications [6] Oncology Segment Performance - Oncology product sales increased by 16% to over $337 million [8] - Sales of chemotherapy drug Rylaze/Enrylaze reached more than $108 million, up nearly 7% year over year, beating the Zacks Consensus Estimate of $106 million [8] - Zepzelca, for small-cell lung cancer, recorded sales over $90 million, up 15% year over year [8] Operating Costs - Adjusted selling, general and administrative expenses (SG&A) rose about 12% year over year to $360.5 million, primarily due to higher compensation-related expenses [11] - Adjusted research and development (R&D) expenses decreased by 14% to $190 million, mainly due to lower clinical program costs [11] Full-Year 2025 Results - For the full year, Jazz reported adjusted EPS of $8.38, down 54% year over year [12] - Total revenues for the year rose 5% year over year to $4.3 billion, including neuroscience and oncology net product sales of $2.9 billion and $1.1 billion, respectively [12] 2026 Guidance - Jazz expects total revenues for 2026 to be in the range of $4.25 billion to $4.50 billion, indicating a 2.5% year-over-year growth at the midpoint [13] - The company anticipates double-digit growth across its combined epilepsy and oncology franchises, while Xywav sales are projected to remain flat or increase by a mid-single-digit percentage [14] - Adjusted SG&A expenses are expected to be between $1.26 billion and $1.32 billion, while adjusted R&D expenses are projected to be in the range of $725 million to $775 million [14]